Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 32Triple Negative Breast Neoplasms 26Carcinoma, Transitional Cell 9Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 8Urinary Bladder Neoplasms 7Lung Neoplasms 4Endometrial Neoplasms 3Brain Neoplasms 3Small Cell Lung Carcinoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Advanced Breast Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urothelial Bladder Carcinoma 1Triple Negative Locally Advanced Non-resectable Breast Cancer 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

Paclitaxel 71Bevacizumab 64Carboplatin 56pembrolizumab 46olaparib 32Gemcitabine 29Specimen Handling 27Cyclophosphamide 26liposomal doxorubicin 24Magnetic Resonance Spectroscopy 24Cisplatin 22niraparib 21Taxes 19Nivolumab 18fludarabine 17Topotecan 17Biopsy 17Doxorubicin 14Immunoglobulin G 13Disulfides 13Fulvestrant 12Blood Specimen Collection 11durvalumab 10Oxaliplatin 10mirvetuximab soravtansine 9aldesleukin 9Surveys and Questionnaires 9Ipilimumab 9Fluorouracil 9cemiplimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × sacituzumab govitecan × 1 year × Clear all
NCT06028932 2026-03-05

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Yale University

Phase 2 Active not recruiting
20 enrolled
Gynecologic

Ovarian Neoplasms

NCT06040970 2025-12-02

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Icahn School of Medicine at Mount Sinai

Phase 1/2 Recruiting
54 enrolled
Gynecologic

Ovarian Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡